LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.37
+0.35%Margins
Gross margin
-8537.0%
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-106.3%
Return on equity
-79.9%
Return on assets
-70.9%
Return on invested capital
0.00x
Asset turnover
-$133.3M
Cash from operations
$8.33
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026